oxazolidin-2-one has been researched along with Atherogenesis in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Angermann, C; Armitage, J; Baigent, C; Barter, P; Baxter, A; Blaustein, R; Bowman, L; Braunwald, E; Brenner, S; Cannon, C; Chen, F; Chen, Y; Chen, Z; Collins, R; Dayanandan, R; DeLucca, P; Ertl, G; Fabbri, G; Fajardo-Moser, M; Goodenough, R; Goto, S; Gray, A; Hao, D; Haynes, R; Herrington, W; Hill, M; Hopewell, JC; Knott, C; Landray, M; Lay, M; Liu, J; Lucci, D; Macdonnell, S; Maggioni, A; Mihaylova, B; Mitchel, Y; Mosegaard, S; Murphy, K; Sammons, E; Stevens, W; Tobert, J; Valdes-Marquez, E; Wallendszus, K; Wanner, C; Wincott, E; Wiviott, S; Wuhan, B; Zhang, H | 1 |
| Bowman, L; Braunwald, E; Cannon, CP; Chen, F; Collins, R; Hopewell, JC; Landray, MJ; Sammons, E; Stevens, W; Wallendszus, K; Wiviott, SD | 1 |
| Andou, T; Fujimoto, J; Hara, R; Hayashi, R; Iida, K; Imanishi, M; Kawamoto, T; Kubo, K; Maekawa, T; Masada, S; Matsui, J; Matsunaga, N; Miyahisa, I; Nagase, H; Noguchi, N; Okamoto, R; Takagahara, S; Tamura, YO; Tohyama, K | 1 |
| Badimon, L | 1 |
| Filardi, PP; Maggioni, AP | 1 |
| Boffa, MB; Koschinsky, ML | 1 |
| deGoma, EM; Rader, DJ | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K | 1 |
| Inazu, A; Mabuchi, H; Nohara, A | 1 |
| Quintão, EC | 1 |
| Shinkai, H | 1 |
| Masson, D | 1 |
| Stroes, ES; Vergeer, M | 1 |
| Böhm, M; Laufs, U; Pöss, J | 1 |
| Gurfinkel, R; Joy, TR | 1 |
| Hirayama, S; Miida, T | 1 |
| Inazu, A | 1 |
| Burnett, JR; Hooper, AJ | 1 |
| Deanfield, J; Kastelein, J; Landmesser, U; Lüscher, TF; von Eckardstein, A | 1 |
| Duriez, P | 1 |
11 review(s) available for oxazolidin-2-one and Atherogenesis
| Article | Year |
|---|---|
Screening for and management of elevated Lp(a).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atherosclerosis; Biomarkers; Canada; Female; Humans; Lipoprotein(a); Male; Mass Screening; Oligonucleotides; Oxazolidinones; Predictive Value of Tests; Risk Factors | 2013 |
Future of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2014 |
Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Topics: Animals; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Humans; Lipid Metabolism, Inborn Errors; Oxazolidinones | 2014 |
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds | 2016 |
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Esters; Humans; Oxazolidinones; Patents as Topic; Quinolines; Sulfhydryl Compounds | 2009 |
Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Topics: Animals; Area Under Curve; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Inhibitory Concentration 50; Molecular Structure; Oxazolidinones; Randomized Controlled Trials as Topic; Structure-Activity Relationship | 2009 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome | 2010 |
Anacetrapib: hope for CETP inhibitors?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Oxazolidinones; Treatment Outcome | 2011 |
[Recent advances in the research on HDL subfraction].
Topics: Atherosclerosis; Biomarkers; Chemical Fractionation; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Disease; High-Density Lipoproteins, Pre-beta; Humans; Lipoprotein(a); Oxazolidinones; Predictive Value of Tests | 2010 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
2 trial(s) available for oxazolidin-2-one and Atherogenesis
| Article | Year |
|---|---|
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Topics: Adult; Atherosclerosis; Atorvastatin; Double-Blind Method; Humans; Myocardial Infarction; Oxazolidinones; Treatment Outcome | 2022 |
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Oxazolidinones | 2017 |
8 other study(ies) available for oxazolidin-2-one and Atherogenesis
| Article | Year |
|---|---|
Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors.
Topics: Administration, Oral; Animals; Arachidonic Acid; Atherosclerosis; Biological Availability; Delta-5 Fatty Acid Desaturase; Drug Discovery; Fatty Acid Desaturases; Liver; Mice; Oxazolidinones; Structure-Activity Relationship | 2017 |
CETP inhibition and HDL: what is the trial REVEALing?
Topics: Atherosclerosis; Cholesterol Ester Transfer Proteins; Humans; Oxazolidinones | 2018 |
[The REVEAL study].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein | 2015 |
Anacetrapib.
Topics: Atherosclerosis; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Dyslipidemias; Humans; Hypercholesterolemia; Oxazolidinones | 2010 |
Anacetrapib, a cholesteryl ester transfer protein inhibitor.
Topics: Animals; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones | 2012 |
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Topics: Acute Coronary Syndrome; Amides; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Early Termination of Clinical Trials; Esters; Humans; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2012 |
Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Heart Diseases; Humans; Oxazolidinones; Quinolines; Risk Factors | 2008 |